2017-04-06
177Lu-Dotatate for Midgut Neuroendocrine Tumors
Publication
Publication
New England Journal of Medicine , Volume 376 - Issue 14 p. 1391- 1392
To the Editor:
Although the results of the multicenter, randomized, controlled Neuroendocrine Tumors Therapy (NETTER-1) trial reported by Strosberg et al. (Jan. 12 issue) validate the experience gained over the past decade by many institutions, we think that they overstate the toxic effects of lutetium-177 (177Lu)–Dotatate and potentially underestimate its efficacy relative to other potential therapies for these tumors. [...]
Additional Metadata | |
---|---|
doi.org/10.1056/NEJMc1701616, hdl.handle.net/1765/105522 | |
New England Journal of Medicine | |
Organisation | Erasmus MC: University Medical Center Rotterdam |
Strosberg, J., & Krenning, E. (2017). 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 376(14), 1391–1392. doi:10.1056/NEJMc1701616 |